These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 31269742)

  • 1. Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment.
    Manzella L; Massimino M; Stella S; Tirrò E; Pennisi MS; Martorana F; Motta G; Vitale SR; Puma A; Romano C; Di Gregorio S; Russo M; Malandrino P; Vigneri P
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Insights in Thyroid Cancer and p53 Family Proteins.
    Manzella L; Stella S; Pennisi MS; Tirrò E; Massimino M; Romano C; Puma A; Tavarelli M; Vigneri P
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy.
    Hua H; Kong Q; Yin J; Zhang J; Jiang Y
    J Hematol Oncol; 2020 Jun; 13(1):64. PubMed ID: 32493414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy: a new hope for thyroid carcinomas.
    Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on thyroid cancer treatment.
    Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V
    Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IGF-I axis in thyroid carcinoma.
    Ciampolillo A; De Tullio C; Perlino E; Maiorano E
    Curr Pharm Des; 2007; 13(7):729-35. PubMed ID: 17346187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
    Russo MA; Kang KS; Di Cristofano A
    Thyroid; 2013 Oct; 23(10):1284-93. PubMed ID: 23509868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on molecular biology of thyroid cancers.
    Omur O; Baran Y
    Crit Rev Oncol Hematol; 2014 Jun; 90(3):233-52. PubMed ID: 24405857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.
    Tirrò E; Martorana F; Romano C; Vitale SR; Motta G; Di Gregorio S; Massimino M; Pennisi MS; Stella S; Puma A; Gianì F; Russo M; Manzella L; Vigneri P
    Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31540307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Therapy in Thyroid Cancer: State of the Art.
    Valerio L; Pieruzzi L; Giani C; Agate L; Bottici V; Lorusso L; Cappagli V; Puleo L; Matrone A; Viola D; Romei C; Ciampi R; Molinaro E; Elisei R
    Clin Oncol (R Coll Radiol); 2017 May; 29(5):316-324. PubMed ID: 28318881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.
    Spitzweg C; Bible KC; Hofbauer LC; Morris JC
    Lancet Diabetes Endocrinol; 2014 Oct; 2(10):830-42. PubMed ID: 24898835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
    Borson-Chazot F; Dantony E; Illouz F; Lopez J; Niccoli P; Wassermann J; Do Cao C; Leboulleux S; Klein M; Tabarin A; Eberle MC; Benisvy D; de la Fouchardière C; Bournaud C; Lasolle H; Delahaye A; Rabilloud M; Lapras V; Decaussin-Petrucci M; Schlumberger M
    Thyroid; 2018 Sep; 28(9):1174-1179. PubMed ID: 30105951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.
    Chu YH; Wirth LJ; Farahani AA; Nosé V; Faquin WC; Dias-Santagata D; Sadow PM
    Mod Pathol; 2020 Dec; 33(12):2458-2472. PubMed ID: 32737449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Emerging Role of Insulin Receptor Isoforms in Thyroid Cancer: Clinical Implications and New Perspectives.
    Vella V; Malaguarnera R
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30513575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
    You L; Liu C; Tang H; Liao Y; Fu S
    Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): from bench to bedside.
    Abdel-Rahman O
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):45-54. PubMed ID: 25560732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting insulin-like growth factor in breast cancer therapeutics.
    Karamouzis MV; Papavassiliou AG
    Crit Rev Oncol Hematol; 2012 Oct; 84(1):8-17. PubMed ID: 22424863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
    Rivera M; Ghossein RA; Schoder H; Gomez D; Larson SM; Tuttle RM
    Cancer; 2008 Jul; 113(1):48-56. PubMed ID: 18484584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiated thyroid carcinomas from children and adolescents express IGF-I and the IGF-I receptor (IGF-I-R). Cancers with the most intense IGF-I-R expression may be more aggressive.
    Gydee H; O'Neill JT; Patel A; Bauer AJ; Tuttle RM; Francis GL
    Pediatr Res; 2004 Apr; 55(4):709-15. PubMed ID: 14973173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.